ByTrending Posts
BioMarin Announces Agreement to Acquire Amicus Therapeutics in…
San Rafael, CA — BioMarin Pharmaceutical Inc. today announced that it has entered into a definitive agreement to…
Bristol Myers Squibb Unveils “Mosaic” AI Content Hub…
Mumbai, India Bristol Myers Squibb (BMS) today announced the launch of Mosaic, a new artificial intelligence–enabled content hub…
Endpoints Signal Report Finds Nearly Half of Biopharma…
Based on Endpoints Signal Pulse Report | December 2025 A new Signal Pulse Report from Endpoints News reveals…
Chai Discovery Becomes Newest AI Unicorn Following $130…
Company valued at $1.3 billion as investors back AI-native drug discovery platform San Francisco, California Chai Discovery today…
PhaseV Reports Breakthrough Year in 2025, Marking Transition…
Boston, Massachusetts PhaseV announced today that 2025 marked a defining year for the company, highlighted by record revenue…
Takeda Announces Positive Phase III Results for AI-Discovered…
Tokyo, Japan – December 19, 2025 – Takeda Pharmaceutical Company Limited today announced successful results from two Phase…
Geneva inaugurates first artificial intelligence health hub at…
GENEVA, Dec. 8, 2025 — Geneva has officially inaugurated its first artificial intelligence health hub at Campus Biotech,…
Cradle AI-powered protein engineering platform serving six of…
AMSTERDAM and ZURICH, Dec. 16, 2025 — Cradle, an enterprise-grade AI software platform for protein engineering, today announced…
Adaptive Biotechnologies and Pfizer Announce Strategic Research Collaboration…
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis. A data licensing agreement to…
Trending Posts
Latest Stories
Will the European Commission’s New Health Policy Package Accelerate Biotech, AI, and Medical Device Innovation?
The European Commission has unveiled a new health policy package to strengthen innovation, competitiveness, and…
U.S. FDA Approves JASCAYD® for Progressive Pulmonary Fibrosis – A New Treatment Option for Adults?
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD® (nerandomilast)…
Are Galux and Boehringer Ingelheim Pioneering AI in Precision Protein Design?
December 17, 2025 — Galux, a South Korean biotech company focused on AI-driven protein therapeutics,…
Has the FDA Approval of Breyanzi Expanded CAR T Cell Therapy Options for Marginal Zone Lymphoma Patients?
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi,…
Gallery
